Novo Nordisk (NYSE: NVO; Copenhagen: NOVO-B) announced Monday September 14, 2026 the rollout of its updated corporate identity: the operating brand is now simply 'Novo' with the tagline 'Lasting health starts now' plus a new culture framework called 'The Novo Way,' anchored by a refreshed version of the historic Apis bull logo. The legal entity name Novo Nordisk A/S is unchanged, and the NYSE ticker (NVO) and Copenhagen (NOVO-B) tickers remain. CEO Mike Doustdar is expected to detail the strategic backing for the rebrand at the September 21 Capital Markets Day in London — the first Novo Capital Markets Day since Doustdar was named CEO and following the Morgan Stanley Underweight downgrade on Friday September 11 (DKK 250 target, semaglutide patent cliff concerns), Barclays trim from DKK 310 to DKK 300, and HSBC target raise to DKK 320 (Hold). The rebrand pairs with an operational push to regain U.S. Wegovy/Ozempic prescription share against Lilly's tirzepatide franchise, plus the September 16 Anthropic Claude Science R&D collaboration, September 7 STEP Young pediatric semaglutide win, and September 4-7 ziltivekimab HERMES + ATHENA heart-failure trial terminations that have narrowed the non-GLP-1 diversification story.
STAT News published Tuesday September 15, 2026 a landscape piece flagging that obesity drug developers have expanded pediatric trial testing to include children as young as six years old, extending the age range down from the Wegovy 12-and-older U.S. label. Novo Nordisk's STEP Young Phase 3 (topline reported September 7) tested once-weekly semaglutide in 165 children aged 6 to under 12 with obesity: 40.4% of the semaglutide group achieved a BMI below the obesity threshold at week 68 versus 0% on placebo, with no new safety concerns and no signals for growth or pubertal development. STAT flagged additional pediatric-obesity trial activity following the January 2023 AAP Clinical Practice Guideline endorsement of medication therapy for children aged 12+ and consideration in ages 6-11. The September 4 Pediatrics journal publication documented a 310-fold increase in GLP-1 prescribing to U.S. children aged 8-11 with obesity between 2019 and mid-2026 (0.03% to 9.3%), with 93.7% of recipients having severe obesity and 65.2% having weight-related comorbidities. Full STEP Young results are scheduled for ObesityWeek 2026 (November 14-17, Washington DC). No Wegovy sNDA for ages under 12 has been filed as of September 15, 2026.
A study published September 4, 2026 in the American Academy of Pediatrics journal Pediatrics (DOI: 10.1542/peds.2026-077048) documented a 310-fold increase in GLP-1 receptor agonist prescribing in U.S. children aged 8 to 11 without diabetes and with obesity between 2019 and mid-2026 — from 0.03% of eligible children in 2019 to 9.3% in 2026. Prescribing captured liraglutide, semaglutide, and tirzepatide across the age group. Recipient characteristics: 93.7% had class II or III severe obesity at baseline, 65.2% had at least one weight-related comorbidity, and approximately 25% had prediabetes. Socioeconomic gradients were substantial: children in upper-income communities were prescribed GLP-1s at 55% higher rates than those in lower-income communities. The trend accelerated notably following the December 2022 FDA approval of Wegovy for adolescents 12 and older (implicit off-label use in the younger cohort) and shifted further after the AAP's January 2023 pediatric obesity clinical practice guideline. FoodNavigator syndicated the study September 10, 2026 alongside broad coverage this week; the data show how quickly clinical practice moved ahead of the STEP Young Phase 3 topline announced September 7.